Higher Risk of Malignancy
The Nodify CDT test helps identify patients who may benefit from timely intervention with results in one day.* The test measures 7 autoantibodies associated with tumor antigens to help providers detect lung cancer across all histologies and stages.1,2
Download example test result report
The Nodify XL2 test helps identify patients who may benefit from computed tomography (CT) surveillance with results within five days. The test is an integrated classifier that measures the ratio of two proteins (LG3BP and C163A) combined with several clinical and radiological factors to help identify those nodules that are likely benign.